SGLT2 Inhibitors in Cardiovascular-Kidney-Metabolic Syndrome: Drugs Unifying Heart, Kidney, and Metabolism Pharmacotherapy

More on Cardiovascular-kidney-metabolic syndrome

• SGLT2 inhibitors raise genital but not urinary infection risk

  Clinical Pharmacology and Therapeutics · 4 Oct 2026

• Blood proteins improve early cardiometabolic risk prediction

  Diabetes, Obesity & Metabolism · 4 Oct 2026

• NMR metabolomics improves prediction of cardiometabolic diseases

  medRxiv · 4 Oct 2026

  

• Cumulative non-HDL cholesterol is linked to CVD risk

  Journal of Diabetes and Metabolic Disorders · 4 Oct 2026